Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388525 | 0.83 | ESR1 (0.41) | ESR1ESR2CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL4379468 | 0.82 | ESR1 (0.44) | ESR1ESR2CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL4384123 | 0.82 | ESR1 (0.41) | ESR1ESR2SMN1; SMN2CYP3A4HSD17B1 | |
| SCHEMBL4387012 | 0.78 | ESR1 (0.39) | ESR1ESR2TSHRCYP3A4HIF1A | |
| SCHEMBL4382880 | 0.76 | ESR1 (0.47) | ESR1ESR2CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL4382873 | 0.73 | CNR2 (0.37) | ESR1ESR2ALDH1A1 | |
| SCHEMBL4388187 | 0.72 | HDAC4 (0.39) | SMN1; SMN2ALDH1A1TSHRTP53GCGR | |
| SCHEMBL4384914 | 0.72 | ESR1 (0.38) | ESR1ESR2SMN1; SMN2 | |
| SCHEMBL4385900 | 0.72 | CNR2 (0.40) | ESR1ESR2ALDH1A1 | |
| SCHEMBL4385019 | 0.71 | HDAC4 (0.43) | SMN1; SMN2TP53GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | ESR1 610/4885ESR2 1033/4885SMN1; SMN2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.